Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Return on Capital Employed: 2011-2025

Historic Return on Capital Employed for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to 1.12%.

  • Northwest Biotherapeutics' Return on Capital Employed fell 93.00% to 1.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.12%, marking a year-over-year decrease of 93.00%. This contributed to the annual value of 1.62% for FY2024, which is 193.00% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Return on Capital Employed is 1.12%, which was down 4.91% from 1.18% recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Return on Capital Employed ranged from a high of 6.51% in Q2 2023 and a low of 0.23% during Q3 2021.
  • Over the past 3 years, Northwest Biotherapeutics' median Return on Capital Employed value was 2.05% (recorded in 2024), while the average stood at 2.64%.
  • Per our database at Business Quant, Northwest Biotherapeutics' Return on Capital Employed surged by 573bps in 2023 and then crashed by 427bps in 2024.
  • Over the past 5 years, Northwest Biotherapeutics' Return on Capital Employed (Quarterly) stood at 0.53% in 2021, then increased by 18bps to 0.71% in 2022, then surged by 287bps to 3.58% in 2023, then tumbled by 192bps to 1.65% in 2024, then plummeted by 93bps to 1.12% in 2025.
  • Its Return on Capital Employed stands at 1.12% for Q3 2025, versus 1.18% for Q2 2025 and 1.22% for Q1 2025.